Internal Radiation Therapy in Treating Patients With Low-Risk Prostate Cancer
This phase II trial studies how well internal radiation therapy works in treating patients with low-risk prostate cancer. Internal radiation uses radioactive material placed directly into or near a tumor to kill tumor cells.
Adenocarcinoma of the Prostate
Recurrent Prostate Cancer
Stage I Prostate Cancer
Stage IIA Prostate Cancer
Stage IIB Prostate Cancer
Radiation: image-guided radiation therapy
Other: laboratory biomarker analysis
|Study Design:||Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||A Phase II Study of Targeted Brachytherapy for Low Risk Prostate Cancer Patients|
- Biochemical PSA control using the Phoenix definition of PSA nadir + 2 [ Time Frame: 5 years ] [ Designated as safety issue: No ]
- Grade 3-5 acute toxicity genitourinary (GU) and gastrointestinal (GI) toxicity, graded based on NCI CTCAE v4.0 [ Time Frame: 3 months ] [ Designated as safety issue: Yes ]
- Grade 3-5 late toxicity GU and GI toxicity, graded based on NCI CTCAE v4.0 [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
- Changes in health related quality of life (HR-QOL) as determined by EPIC scores [ Time Frame: Up to 24 months ] [ Designated as safety issue: No ]
- Changes in HR-QOL as determined by IIEF scores [ Time Frame: Up to 24 months ] [ Designated as safety issue: No ]
- Changes in HR-QOL as determined by IPSS scores [ Time Frame: Up to 24 months ] [ Designated as safety issue: No ]
|Study Start Date:||March 2012|
|Estimated Primary Completion Date:||March 2015 (Final data collection date for primary outcome measure)|
Experimental: Treatment (image-guided HDR brachytherapy)
Patients undergo 3 fractions of image-guided HDR brachytherapy over 2 days.
Undergo image-guided HDR brachytherapy
Other Names:Radiation: image-guided radiation therapy
Undergo image-guided HDR brachytherapyOther: laboratory biomarker analysis
I. To determine long term 5 year prostate specific cancer (PSA) biochemical control using the Phoenix definition of PSA nadir + 2 of targeted hemi-gland brachytherapy.
I. To assess acute and late toxicity outcomes following targeted brachytherapy according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0.
II. To determine changes from baseline in health-related quality of life indicators using the validated Expanded Prostate Cancer Index Composite (EPIC) questionnaire, International Index of Erectile Function (IIEF) questionnaire, and International Prostate Symptom Score (IPSS) questionnaire.
III. To assess the potential value of multiparametric magnetic resonance imaging, including dynamic contrast enhancement perfusion imaging and diffusion tensor neurovascular tactographic imaging in predicting the development of equivocal disease (ED) following radiation treatment.
Patients undergo 3 fractions of image-guided high-dose rate (HDR) brachytherapy over 2 days.
After completion of study treatment, patients are followed up every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.
|United States, California|
|Jonsson Comprehensive Cancer Center||Recruiting|
|Los Angeles, California, United States, 90095|
|Contact: Mitchell R. Kamrava 888-798-0719 firstname.lastname@example.org|
|Principal Investigator: Mitchell R. Kamrava|
|Principal Investigator:||Mitchell Kamrava||Jonsson Comprehensive Cancer Center|